Company intelligence / Profile preview

Exolvo Biosciences

Ownership: Private
Development stage: Preclinical

Overview

Exolvo Biosciences has developed a proprietary smart capsule technology enabling oral delivery of large, complex molecules such as biologics. The company’s approach eliminates the need for injections, aiming to improve patient adherence and accessibility. As of mid–2025, the company remains in preclinical development with no published clinical results.

Therapeutic areas: OtherCardiovascularImmunology
Modalities: BiologicsLarge MoleculesPeptidesProteins
Industry: Biotech

Partnerships

NLC Health VenturesVerily Life Sciences / Google X Moonshot Program

Beyond the preview

Go deeper on Exolvo Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exolvo Biosciences.

Explore the full profile